Revolution Medicines Announces Positive Phase 3 RASolute 302 Data for Daraxonrasib in Pancreatic Cancer

What happened

Revolution Medicines reported positive results from the Phase 3 RASolute 302 trial evaluating daraxonrasib in second-line metastatic pancreatic cancer, with data presented at the 2026 ASCO Plenary Session. The trial met its primary endpoint, demonstrating a statistically significant improvement in overall survival versus investigator's choice chemotherapy, validating the RAS(ON) inhibitor platform in a difficult-to-treat indication. The company will host an investor call on May 31 to discuss the results and next steps, including potential regulatory filings. Prior to this readout, the stock traded at ~$98, already reflecting high expectations for success and M&A optionality, with the master report rating it a potential sell due to binary risk. The positive outcome removes that binary risk but leaves the question of whether the magnitude of benefit justifies the current ~$19 billion market cap, especially given future royalty obligations and commercial execution challenges.

Implication

The positive RASolute 302 results validate daraxonrasib's efficacy in second-line pancreatic cancer, a major derisking event. However, the master report noted the stock at ~$98 already priced in high odds of success and M&A optionality. With data now public, near-term upside may be limited as the market prices in approval and peak sales. Investors should assess whether the magnitude of benefit justifies the full $19B valuation, especially given royalty encumbrances and commercial challenges. A cautious approach: lock in gains if the stock surges, and wait for further details on competitive differentiation and peak sales potential before re-entering.

Thesis delta

The earlier thesis anticipated no major positive catalysts before 2026 Phase 3 data; the positive readout now provides that catalyst. The previous 'potential sell' rating was based on risk of disappointment; with success, the investment case moves to a 'hold' or 'partial profit-taking' stance. The key question shifts from 'will it work?' to 'how much is it worth?' given already high expectations.